On April 5, 2022 Foundation Medicine, Inc. reported that the company and its collaborators will present a total of nine studies, including two clinical science symposia presentations and seven poster discussions, at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 8-13 (Press release, Foundation Medicine, APR 5, 2022, View Source [SID1234611468]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights of these presentations include:
Two studies spotlighting the concordance between Foundation Medicine’s tissue and blood-based comprehensive genomic profiling (CGP) tests and their complementary value as tools to provide genomic insights to researchers and clinicians.
Data on Foundation Medicine’s new algorithm to predict homologous recombination deficiency (HRD) status and identify patients who may be candidates for PARP inhibitors across multiple disease types. Patient identification for PARP inhibitors remains a challenge, but these findings suggest that HRD status, including indel and copy number features, is associated with instability beyond ovarian cancer.
A new study leveraging existing data to identify 165 ancestry-associated features across multiple common cancer types. These findings help address the lack of knowledge about ancestry-specific alterations in an effort to overcome barriers to implementing precision medicine, including inequities in genetic testing, targeted treatment and clinical trial design for cancer patients from underserved populations.
"Data being presented at this year’s AACR (Free AACR Whitepaper) meeting emphasize our role as an essential partner for our collaborators who are working to identify patients most likely to benefit from new precision therapies," said Priti Hegde, PhD, chief scientific officer at Foundation Medicine. "Our research also highlights how the data derived from our portfolio of tests can shape the future of cancer care and research, including through our novel HRD algorithm."
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at AACR (Free AACR Whitepaper), please visit AACR (Free AACR Whitepaper).org.
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #AACR22 and visit us in person at booth #2301.
Abstract #
Title
Collaborator
Product
Clinical Science Symposia
2139
Monday, April 11
2:35 PM – 2:50 PM
Evaluation of tissue- and plasma-derived tumor mutational burden and genomic alterations of interest from the CheckMate 848 clinical trial
Bristol Myers Squibb
Clinical trial assay based on FoundationOne CDx & Foundation Medicine bTMB Clinical Trial Assay
CT031
Monday, April 11
3:20 PM – 3:30 PM
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity
Pfizer
Clinical trial assay based on FoundationOne CDx
Posters
57/18
Sunday, April 10
1:30 PM – 5:00 PM
Patients with germline ATM mutations develop clonal hematopoiesis characterized by co-occurrence of multiple somatic ATM alterations
FoundationCore
753/9
Monday, April 11
9:00 AM – 12:30 PM
Comprehensive genomic profiling (CGP) reveals site-specific enrichment of immunotherapy biomarkers and targetable alterations in non-small cell lung cancer (NSCLC) metastasis
FoundationCore
798/7
Monday, April 11
9:00 AM – 12:30 PM
Comprehensive genomic profiling of tissue and liquid biopsies reveals the landscape of reversion mutations
FoundationCore
1166/13
Monday, April 11
9:00 AM – 12:30 PM
Leveraging existing data to identify ancestry-associated features across multiple cancer types
Dana Farber Cancer Institute
FoundationCore
1243/15
Monday, April 11
9:00 AM – 12:30 PM
Identification of aneuploidy biomarkers associated with response to first-line treatment of metastatic pancreatic cancer
Foundation Medicine and Flatiron Health’s Clinicogenomic Database
1249/21
Monday, April 11
9:00 AM – 12:30 PM
Development of a pan-cancer algorithm to predict homologous recombination deficiency and sensitivity to PARPi therapy
University of Minnesota
Foundation Medicine and Flatiron Health’s Clinicogenomic Database & FoundationCore
3413/19
Tuesday, April 12
1:30 PM – 5:00 PM
Clinical utility of circulating tumor DNA sequencing with a large panel: The experience of Gustave Roussy/ National Center for Precision Medicine (PRISM)
Gustave Roussy Cancer Center
FoundationOne Liquid CDx